This MedLibrary.org supplementary page on Dosulepin is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. (October 2007) |
 |
|
|
Dosulepin hydrochloride
|
|
| Systematic (IUPAC) name | |
| 3-(dibenzob,ethiepin-11(6H)-ylidene)-N,N-dimethylpropan-1-amine | |
| Identifiers | |
| CAS number | |
| ATC code | N06 |
| PubChem | |
| Chemical data | |
| Formula | C19H21NS |
| Mol. mass | 331.9 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 30% |
| Metabolism | Hepatic |
| Half life | 20 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
C |
| Legal status |
℞ Prescription only |
| Routes | Oral |
Dosulepin hydrochloride (INN) (formerly the BAN dothiepin hydrochloride) is an antidepressant of the tricyclic family. It is sold under the brand names Prothiaden, Dothep and Thaden.
Contents |
Indications
Dosulepin is relatively mild and is used for low-level anxiety depression and similar disorders as well as the treatment of chronic and ongoing pain disorders, particularly where insomnia and/or loss of appetite are present. It can take between two and four weeks of regular usage to become effective; it is often started at a low level and the dosage increased if this is ineffective. The drug causes drowsiness as a side-effect, and this may be used as part of the treatment, since anxiety-depressive patients may have difficulty sleeping; it can also be combined with other drugs such as temazepam.
Dosage
Adults: Initially 75 mg/day in divided doses or as a single dose at night, increasing to 150 mg/day. In certain circumstances, e.g. in hospital use or unresponsive patients, dosages up to 300 mg daily have been used.
Suggested regimens: 25 or 50 mg three times daily or, alternatively, 75 or 150 mg as a single dose at night. Should the regimen of 150 mg as a single night-time dose be adopted, it is better to give a smaller dose for the first few days.
Elderly: 50 to 75 mg daily initially. As with any antidepressant, the initial dose should be increased with caution under close supervision. Half the normal adult dose may be sufficient to produce a satisfactory clinical response.
Children: Not recommended. 1
Side effects
The most common side-effects are drowsiness and dry mouth as well as dry eyes. Other less common side-effects may include:
- Constipation
- Abnormally large stools
- Blurred vision
- Tachycardia
- Urinary retention
- tremors, especially of the hands
- Blood disorders
- Hypotension
- Sexual dysfunction
- Sweating
- Increased sensitivity to sunlight and increased vulnerability to sunburn
These side-effects cease when treatment ceases. Alcohol should be avoided whilst taking dosulepin as it may increase some side-effects.
Whilst dosulepin is not addictive, it should not be stopped suddenly as there is a risk of initial withdrawal symptoms which may be mistaken for some of the original indications for the drug:
- Nausea
- Vomiting
- Loss of appetite
- Headache
- Giddiness
- Chills
- Insomnia
- Anxiety
Contra-indications
Contra-indications include:
- Certain conditions of the heart, mainly those affecting the electrical impulses to the heart muscle, particularly arrhythmia or recent heart attack
- Mania.
- Liver disease or thyroid disease
- Epilepsy, phaeochromocytoma, glaucoma or diabetes
- Hypotension, vulnerability to dizziness or fainting
- History of urinary retention or porphyria
Drug interactions
The drug can interact dangerously with vasoconstrictors and should not be taken in combination with phenylephrine or adrenaline in particular.
The sedative effects of other CNS depressants (benzodiazepines such as diazepam and lorazepam, sedative antihistamines, opiates, etc.) may be increased.
This drug should not be started within 2 weeks of stopping a monoamine oxidase inhibitor (MAOI) antidepressant, and should not be co-administered with any selective serotonin reuptake inhibitor (SSRI) antidepressant such as fluoxetine), or any medication which affects the electrical impulses to the heart (e.g. astemizole, halofantrine or terfenadine).
The drug is not recommended for use by children nor to be taken in combination with some other drugs, including herbal remedies.
Overdose
The symptoms and the treatment of an overdose are largely the same as for the other tricyclic antidepressants.
References
See also
|
|||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 19 December 2008, at 09:26.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Dosulepin".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.